|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Imperial College London to Present First Public HBV Data from CN Bio in Vitro Liver Model
New advances in the pre-clinical evaluation of Hepatitis B therapies
September 02, 2014 09:00 AM Eastern Daylight Time
OXFORD, England--(BUSINESS WIRE)--CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, has announced that data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be the subject of oral and poster presentations at three international meetings this Fall, including:
• The 2014 International Meeting on Hepatitis B in Los Angeles, USA (3-6 September, 2014)
• The Viral Hepatitis Congress 2014 in Frankfurt, Germany (9-11 October, 2014)
• The Liver Meeting® 2014*, Boston USA (7-11 November, 2014). CN Bio will also host an Investigator Meeting** on Monday 10th November, which is an invitation-only event for attendees of The Liver Meeting® 2014.
First public presentations
Dr Marcus Dorner, Lead Principle Investigator for the study, commented: “It’s an honour to be invited to present our data at these prestigious meetings, where we’ll show how CN Bio’s Hepatitis B liver disease model accurately recapitulates the full life-cycle of HBV without the need for interventions such as the solvent permeabilization of cells. This makes it a uniquely powerful tool for developing and testing new HBV treatments.”
A breakthrough in HBV research
Dr Emma Sceats, COO at CN Bio said, “The work completed through this collaboration with Dr Dorner and his team represents an important breakthrough. The absence of suitable in vitro and animal models of Hepatitis B limits our ability to effectively analyse the biology and pathology of the disease, making the development of effective drugs very challenging. Hopefully, using new, advanced technologies such as these, novel therapies will reach market more quickly, helping to treat the more than 300 million patients worldwide infected with Hepatitis B.”
*The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases
**This event is not an official function/event of the American Association for the Study of Liver Diseases
About CN Bio Innovations
CN Bio Innovations (CN Bio), formerly Zyoxel Ltd, is part of Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio provides human biomimetic platforms for the testing and development of therapeutics for serious human diseases. Working closely with academic pioneers in the bio-engineering field, CN Bio is developing next generation tissue and disease models which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market.
Contacts
CN Bio Innovations
Ian Taylor
Commercial Director
T: +44 (0) 1865 309 600
E: [email protected]
W: www.cn-bio.com
or
BioStrata
Paul Avery
Managing Director
T: +44 (0) 1223 828 200
E: [email protected]
W: www.biostratamarketing.com
|
|
发表于 2014-9-3 09:46
